Genzyme Sues Lupin Over Generic Renvela Plans

Law360, New York (May 15, 2009, 12:00 AM EDT) -- Genzyme Corp. has sued India-based generics maker Lupin Ltd. over its efforts to make generic Renvela, more than two months after it sued Lupin over an earlier version of the same kidney treatment.

The Cambridge, Mass-based drugmaker filed suit Thursday in the U.S. District Court for the District of Maryland, accusing Lupin of infringing six patents, including four it asserted against Lupin in March over the drug Renagel.

Renagel and Renvela are nonabsorbed, calcium-free, metal-free phosphate binders that are used to control serum phosphorus in patients...
To view the full article, register now.